The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
High-Mobility Group Box-1 in Ischemia-Reperfusion Injury of the Heart
Abstract
Background— High-mobility group box-1 (HMGB1) is a nuclear factor released by necrotic cells and by activated immune cells. HMGB1 signals via members of the toll-like receptor family and the receptor for advanced glycation end products (RAGE). Although HMGB1 has been implicated in ischemia/reperfusion (I/R) injury of the liver and lung, its role in I/R injury of the heart remains unclear. Methods and Results— Here, we demonstrate that HMGB1 acts as an early mediator of inflammation and organ damage in I/R injury of the heart. HMGB1 levels were already elevated 30 minutes after hypoxia in vitro and in ischemic injury of the heart in vivo. Treatment of mice with recombinant HMGB1 worsened I/R injury, whereas treatment with HMGB1 box A significantly reduced infarct size and markers of tissue damage. In addition, HMGB1 inhibition with recombinant HMGB1 box A suggested an involvement of the mitogen-activated protein kinases jun N-terminal kinase and extracellular signal-regulated kinase 1/2, as well as the nuclear transcription factor nuclear factor-κB in I/R injury. Interestingly, infarct size and markers of tissue damage were not affected by administration of recombinant HMGB1 or HMGB1 antagonists in RAGE −/− mice, which demonstrated significantly reduced damage in reperfused hearts compared with wild-type mice. Coincubation studies using recombinant HMGB1 in vitro induced an inflammatory response in isolated macrophages from wild-type mice but not in macrophages from RAGE −/− mice. Conclusions— HMGB1 plays a major role in the early event of I/R injury by binding to RAGE, resulting in the activation of proinflammatory pathways and enhanced myocardial injury. Therefore, blockage of HMGB1 might represent a novel therapeutic strategy in I/R injury.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
HMG-1 as a Late Mediator of Endotoxin Lethality in Mice
Wang, H., Bloom, O., Zhang, M., Vishnubhakat, J. M., Ombrellino, M., Che, J., Frazier, A., Yang, H., Ivanova, S., Borovikova, L., et al. (1999) · Science · doi:10.1126/science.285.5425.248 · Cited by 3,385
Baeuerle, P. A., & Baltimore, D. (1996) · Cell · doi:10.1016/s0092-8674(00)81318-5 · Cited by 3,001
The inflammatory response in myocardial infarction
Frangogiannis, N. (2002) · Cardiovascular Research · doi:10.1016/s0008-6363(01)00434-5 · Cited by 2,011
Park, J. S., Svetkauskaite, D., He, Q., Kim, J.-Y., Strassheim, D., Ishizaka, A., & Abraham, E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306793200 · Cited by 1,562
Andersson, U., Wang, H., Palmblad, K., Aveberger, A.-C., Bloom, O., Erlandsson-Harris, H., Janson, A., Kokkola, R., Zhang, M., Yang, H., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.4.565 · Cited by 1,401
Tian, J., Avalos, A. M., Mao, S.-Y., Chen, B., Senthil, K., Wu, H., Parroche, P., Drabic, S., Golenbock, D., Sirois, C., et al. (2007) · Nature Immunology · doi:10.1038/ni1457 · Cited by 1,372
Self-citationUnderstanding RAGE, the receptor for advanced glycation end products
Bierhaus, A., Humpert, P. M., Morcos, M., Wendt, T., Chavakis, T., Arnold, B., Stern, D. M., & Nawroth, P. P. (2005) · Journal of Molecular Medicine · doi:10.1007/s00109-005-0688-7 · Cited by 1,297
Self-citationThe multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses
Schmidt, A. M., Yan, S. D., Yan, S. F., & Stern, D. M. (2001) · Journal of Clinical Investigation · doi:10.1172/jci14002 · Cited by 1,253
The Receptor for Advanced Glycation End Products (RAGE) Is a Cellular Binding Site for Amphoterin
Hori, O., Brett, J., Slattery, T., Cao, R., Zhang, J., Chen, J. X., Nagashima, M., Lundh, E. R., Vijay, S., Nitecki, D., et al. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.43.25752 · Cited by 1,151
Reversing established sepsis with antagonists of endogenous high-mobility group box 1
Yang, H., Ochani, M., Li, J., Qiang, X., Tanovic, M., Harris, H. E., Susarla, S. M., Ulloa, L., Wang, H., DiRaimo, R., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2434651100 · Cited by 1,126
Cited by
The Biological Basis for Cardiac Repair After Myocardial Infarction: From Inflammation to Fibrosis
Prabhu, S. D., & Frangogiannis, N. G. (2016) · Circulation Research · doi:10.1161/circresaha.116.303577 · Cited by 2,224
The inflammatory response in myocardial injury, repair, and remodelling
Frangogiannis, N. G. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.28 · Cited by 1,738
HMGB1 is a therapeutic target for sterile inflammation and infection
Andersson, U., & Tracey, K. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101323 · Cited by 1,437
Regulation of the Inflammatory Response in Cardiac Repair
Frangogiannis, N. G. (2012) · Circulation Research · doi:10.1161/circresaha.111.243162 · Cited by 1,194
Kang, R., Chen, R., Zhang, Q., Hou, W., Wu, S., Cao, L., Huang, J., Yu, Y., Fan, X.-G., Yan, Z., et al. (2014) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2014.05.001 · Cited by 956
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Ong, S.-B., Hernández-Reséndiz, S., Crespo-Avilan, G. E., Mukhametshina, R. T., Kwek, X.-Y., Cabrera-Fuentes, H. A., & Hausenloy, D. J. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.01.001 · Cited by 918
Maroso, M., Balosso, S., Ravizza, T., Liu, J., Aronica, E., Iyer, A. M., Rossetti, C., Molteni, M., Casalgrandi, M., Manfredi, A. A., et al. (2010) · Nature Medicine · doi:10.1038/nm.2127 · Cited by 842
Self-citationCD24 and Siglec-10 Selectively Repress Tissue Damage–Induced Immune Responses
Chen, G.-Y., Tang, J., Zheng, P., & Liu, Y. (2009) · Science · doi:10.1126/science.1168988 · Cited by 786
Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release
Venereau, E., Casalgrandi, M., Schiraldi, M., Antoine, D. J., Cattaneo, A., De Marchis, F., Liu, J., Antonelli, A., Preti, A., Raeli, L., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120189 · Cited by 720
“…effects of BoxA in models of hepatitis (Sitia et al., 2007), peritonitis (Orlova et al., 2007), ischemia/reperfusion of the heart and the brain (Andrassy et al., 2008; Muhammad et al., 2008), and other ailments, may be entirely attributable to the reduced recruitment of inflammatory cells in…”
BackgroundSelf-citationSchiraldi, M., Raucci, A., Muñoz, L. M., Livoti, E., Celona, B., Venereau, E., Apuzzo, T., De Marchis, F., Pedotti, M., Bachi, A., et al. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20111739 · Cited by 676
Self-citationA Review of Neutrophil Extracellular Traps (NETs) in Disease: Potential Anti-NETs Therapeutics
Mutua, V., & Gershwin, L. J. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-020-08804-7 · Cited by 639
Targeting Inflammation Driven by HMGB1
Yang, H., Wang, H., & Andersson, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00484 · Cited by 636
Pathophysiology of Myocardial Infarction
Frangogiannis, N. G. (2015) · Comprehensive Physiology · doi:10.1002/cphy.c150006 · Cited by 618
Receptor for AGE (RAGE): Signaling mechanisms in the pathogenesis of diabetes and its complications
Ramasamy, R., Yan, S. F., & Schmidt, A. M. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2011.06320.x · Cited by 521
Cellular signalling of the receptor for advanced glycation end products (RAGE)
Xie, J., Méndez, J. D., Méndez-Valenzuela, V., & Aguilar-Hernández, M. M. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.06.013 · Cited by 513
Alarmins: awaiting a clinical response
Chan, J. K., Roth, J., Oppenheim, J. J., Tracey, K. J., Vogl, T., Feldmann, M., Horwood, N., & Nanchahal, J. (2012) · Journal of Clinical Investigation · doi:10.1172/jci62423 · Cited by 511
Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.185 · Cited by 477
High-Mobility Group Box 1, Oxidative Stress, and Disease
Tang, D., Kang, R., Zeh, H. J., & Lotze, M. T. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3356 · Cited by 468
HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins
Bertheloot, D., & Latz, E. (2017) · Cellular & Molecular Immunology · doi:10.1038/cmi.2016.34 · Cited by 455
The Role of Toll-Like Receptor 4 in Infectious and Noninfectious Inflammation
Molteni, M., Gemma, S., & Rossetti, C. (2016) · Mediators of Inflammation · doi:10.1155/2016/6978936 · Cited by 446
The HMGB1 Receptor RAGE Mediates Ischemic Brain Damage
Muhammad, S., Barakat, W., Stoyanov, S., Murikinati, S., Yang, H., Tracey, K. J., Bendszus, M., Rossetti, G., Nawroth, P. P., Bierhaus, A., et al. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2435-08.2008 · Cited by 412
Self-citationThe RAGE axis: A fundamental mechanism signaling danger to the vulnerable vasculature
Yan, S. F., Ramasamy, R., & Schmidt, A. M. (2010) · Circulation Research · doi:10.1161/circresaha.109.212217 · Cited by 381
Platelet-derived HMGB1 is a critical mediator of thrombosis
Vogel, S., Bodenstein, R., Chen, Q., Feil, S., Feil, R., Rheinlaender, J., Schäffer, T. E., Bohn, E., Frick, J.-S., Borst, O., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81660 · Cited by 370
Erratum: Inflammatory processes in cardiovascular disease: a route to targeted therapies
Ruparelia, N., Chai, J. T., Fisher, E. A., & Choudhury, R. P. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.33 · Cited by 363
Byun, K., Yoo, Y., Son, M., Lee, J., Jeong, G.-B., Park, Y. M., Salekdeh, G. H., & Lee, B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.030 · Cited by 357
Targeting HMGB1 in inflammation
Yang, H., & Tracey, K. J. (2010) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2009.11.019 · Cited by 351
Innate immune signaling in cardiac ischemia
Arslan, F., de Kleijn, D. P., & Pasterkamp, G. (2011) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2011.38 · Cited by 347
DAMP Signaling is a Key Pathway Inducing Immune Modulation after Brain Injury
Liesz, A., Dalpke, A., Mracsko, E., Roth, S., Zhou, W., Yang, H., Na, S.-Y., Akhisaroglu, M., Fleming, T., Eigenbrod, T., et al. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.2439-14.2015 · Cited by 334
Self-citationBierhaus, A., & Nawroth, P. P. (2009) · Diabetologia · doi:10.1007/s00125-009-1458-9 · Cited by 314
Self-citationBadylak, S. F. (2014) · Annals of Biomedical Engineering · doi:10.1007/s10439-013-0963-7 · Cited by 307
Disulfide HMGB1 derived from platelets coordinates venous thrombosis in mice
Stark, K., Philippi, V., Stockhausen, S., Busse, J., Antonelli, A., Miller, M., Schubert, I., Hoseinpour, P., Chandraratne, S., von Brühl, M.-L., et al. (2016) · Blood · doi:10.1182/blood-2016-04-710632 · Cited by 305
Self-citationThe innate immune response in reperfused myocardium
Timmers, L., Pasterkamp, G., de Hoog, V. C., Arslan, F., Appelman, Y., & de Kleijn, D. P. V. (2012) · Cardiovascular Research · doi:10.1093/cvr/cvs018 · Cited by 291
Anti‐inflammatory therapies in myocardial infarction: failures, hopes and challenges
Huang, S., & Frangogiannis, N. G. (2018) · British Journal of Pharmacology · doi:10.1111/bph.14155 · Cited by 282
Inflammation in Myocardial Diseases
Marchant, D. J., Boyd, J. H., Lin, D. C., Granville, D. J., Garmaroudi, F. S., & McManus, B. M. (2012) · Circulation Research · doi:10.1161/circresaha.111.243170 · Cited by 282
Oxidative stress-mediated HMGB1 biology
Yu, Y., Tang, D., & Kang, R. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00093 · Cited by 256
High‐mobility group box‐1 in sterile inflammation
Tsung, A., Tohme, S., & Billiar, T. R. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12276 · Cited by 187
Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy
Chelko, S. P., Asimaki, A., Andersen, P., Bedja, D., Amat-Alarcon, N., DeMazumder, D., Jasti, R., MacRae, C. A., Leber, R., Kleber, A. G., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85923 · Cited by 180
Emerging Roles for HMGB1 Protein in Immunity, Inflammation, and Cancer
Ranzato, E., Martinotti, S., & Patrone, M. (2015) · ImmunoTargets and Therapy · doi:10.2147/itt.s58064 · Cited by 127
“New recent data support a novel concept of brain– immune interaction after acute brain lesions in which soluble danger signals from the brain mediate a complex immune-modulatory reaction in the peripheral immune system.(53,54) The HMGB1-RAGE-mediated pathway could be a key mechanism explaining the complex postischemic…”
Tsoporis, J. N., Izhar, S., Leong-Poi, H., Desjardins, J.-F., Huttunen, H. J., & Parker, T. G. (2010) · Circulation Research · doi:10.1161/circresaha.109.195834 · Cited by 118
Pusterla, T., Nèmeth, J., Stein, I., Wiechert, L., Knigin, D., Marhenke, S., Longerich, T., Kumar, V., Arnold, B., Vogel, A., et al. (2013) · Hepatology · doi:10.1002/hep.26395 · Cited by 97
Self-citationRosenblum, J. M., Shimoda, N., Schenk, A. D., Zhang, H., Kish, D. D., Keslar, K., Farber, J. M., & Fairchild, R. L. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903831 · Cited by 80
Increased serum HMGB1 is related to the severity of coronary artery stenosis
Hu, X., Jiang, H., Bai, Q., Zhou, X., Xu, C., Lu, Z., Cui, B., & Wen, H. (2009) · Clinica Chimica Acta · doi:10.1016/j.cca.2009.06.016 · Cited by 75
Metadata
- Authors
- Andrassy, M., Volz, H. C., Igwe, J. C., Funke, B., Eichberger, S. N., Kaya, Z., Buss, S., Autschbach, F., Pleger, S. T., Lukic, I. K., Bea, F., Hardt, S. E., Humpert, P. M., Bianchi, M. E., Mairbäurl, H., Nawroth, P. P., Remppis, A., Katus, H. A., & Bierhaus, A.
- Venue
- Circulation
- Published
- 2008-06-24
- Volume
- 117
- Issue
- 25
- Pages
- 3216-3226
- ISSN
- 0009-7322 (ISSN-L)
- 1524-4539
- OpenAlex
- W2017234408
- Cited by
- 620
- References
- 40
- FWCI
- 21.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.